In a six-dimension evaluation of five long-acting GLP-1 receptor agonists in China for type 2 diabetes, semaglutide had the highest score (76.6) and a Strong Recommendation.
In plain wordsIn a scoring review of five long-acting GLP-1 drugs in China, semaglutide had the highest score and was placed in the review's top recommendation category.
- Peptide
- Semaglutide
- Outcome
- Not applicableComprehensive clinical evaluation score
- Study
n: not reported in source
- Outcome group
- Overall treatment effect · Pharmacology
Measurements
- Comprehensive score
- 76.6 points
- semaglutide
Source sentences
The comprehensive scores were as follows: semaglutide (76.6)
2 context sentences(design, population, supporting numbers)
Semaglutide and dulaglutide, classified as Strong Recommendations, demonstrated superior efficacy (particularly in cardio-renal protection) and overall value.
Dulaglutide, semaglutide, polyethylene glycol loxenatide, tirzepatide, and mazdutide were evaluated using a 100-point scoring system based on drug labels, systematic literature review, and real-world data.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.